New Research Product Shows Impressive Data In TBI

The company recently announced functional data from its ALPHA 1062 intranasal Traumatic Brain Injury (TBI) program. ALPHA-1062 administration significantly, acutely reduced the extent of the functional deficit, and improved functional recovery of TBI in animals compared to untreated animals suffering a TBI. Notably, in four of five functional measures of recovery, the performance of ALPHA-1062 treated group was statistically indistinguishable from that of the uninjured cohort. Not only did ALPHA-1062 demonstrated statistical difference from placebo (injured animal with no treatment) but was indistinguishable from uninjured animals.

The impact of this is that ALPHA-1062 performed as well for most end-points of the trial as non-injured animals. It performed better than vehicle (injured and untreated) in all measures and performed equal to un-injured animals in four of five measures.

In its studies, Alpha Cognition’s team noted that ALPHA-1062 demonstrated (functional) acute recovery from injury, and significantly improved:

• Motor and sensory functional recovery measured by motor skill assessment, sensory/motor skill assessment, and Modified Neurological Severity Score which comprises motor, sensory, balance and reflex assessment;
• Cognitive functional recovery measured by tests which assess recognition memory, and spatial learning and memory;

In a media release on this news for investors, the company’s Chief Scientific Officer, Denis Kay, explained that these preclinical results, combined with the team’s clinical data demonstrating the safety and tolerability of ALPHA-1062, support its continued development for the treatment of TBI, which they believe has the potential to help millions of people who suffer from a TBI each year.

“We are encouraged by the data thus far and confident in our progress towards developing a safe and effective treatment for this underserved population.”

One of the most common treatments for Alzheimer’s disease is galantamine, an acetylcholinesterase inhibitor (AChEI), which unfortunately, comes with known adverse effects including nausea, vomiting, diarrhea and other side effects that make it unpleasant and impractical to continue taking the drug for extended periods of time.

Working towards a new, better solution, Alpha Cognition Inc. is developing treatments for neurodegenerative diseases like Alzheimer’s and Dementia and is developing these novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders.

The team also added that the neuropathological assessment of the brains from each experimental group is ongoing and top line results will be released in Q1, 2022. The company will provide next steps on their TBI program after this data set and guidance from the US Food and Drug Administration. The FDA recently accepted the company’s Investigational New Drug application for ALPHA-1062, to proceed with the pivotal clinical phase of the development program.

According to data gathered from DRG Executive Insights, TBI is a highly prevalent and increasingly common deadly condition, with nearly three million diagnosed events occurring in the United States alone in 2019.

This company has an impressive pipeline of assets that coming to the market, and it is poised to make 2022 of the most exciting years in its history. Most importantly, it is a significant milestone for patients and their caregivers. Alpha Cognition offers the opportunity to bring a new therapy that could be impactful. In the course of the work accomplished by this team, there is a great opportunity for investor reward. For those who follow the story already, there is plenty of progress to be made on the horizon that is reason enough to get excited.

For regular updates, visit www.alphacognition.com.




FULL DISCLOSURE: This is a paid article produced by Stockhouse Publishing.